{"product_id":"penn-medicine-hypertension-lipids-and-approaches-to-cv-pharmacologic-risk-reduction-what-s-new-in-2022","title":"Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022","description":"\u003cheader class=\"section__headings section__headings___edc6e\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"field field-name-field-course-summary field-type-text-with-summary field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cdiv class=\"card-header bg-transparent py-4 px-3\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"prod-title\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv\u003e\n\u003ch3 class=\"product_title entry-title\"\u003ePenn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv\u003ePenn Medicine CV Pharmacologic Risk Reduction\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003eInclude: 13 videos + 16 pdfs, size: 3.02 GB\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eDate \u0026amp; Location\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eFriday, September 30, 2022, 7:45 AM – 2:00 PM, Virtual, Philadelphia, PA\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eCourse Overview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cp\u003eCVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.\u003c\/p\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003ePenn Medicine CV Pharmacologic Risk Reduction\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINE\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cem\u003eAfter completing this activity, participants should be able to:\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eSelect appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations\u003c\/li\u003e\n\u003cli\u003eIdentify appropriate blood pressure goals and management in several special patient populations\u003c\/li\u003e\n\u003cli\u003eReview the controversies regarding the appropriate treatment of and management of pregnant patients at risk for CVD.\u003c\/li\u003e\n\u003cli\u003eAchieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia in young patients.\u003c\/li\u003e\n\u003cli\u003eApply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBP Goals and Use of Thiazides in Advanced CKD.mp4\u003cbr\u003e\nBP Goals and Use of Thiazides in Advanced CKD.pdf\u003cbr\u003e\nBP Goals Management in Elderly (STEP Trial and SPRINT).mp4\u003cbr\u003e\nBP Goals Management in Elderly (STEP Trial and SPRINT).pdf\u003cbr\u003e\nBP22_Brochure_v4.pdf\u003cbr\u003e\nCholesterol.mp4\u003cbr\u003e\nCholesterol.pdf\u003cbr\u003e\nClinical Case Discussion FOUNDATIONS- REFRESHER OF THE CURRENT GUIDELINES.pdf\u003cbr\u003e\nClinical Case Discussion SPECIAL POPULATIONS.pdf\u003cbr\u003e\nDM Weight loss.mp4\u003cbr\u003e\nDM Weight loss.pdf\u003cbr\u003e\nHypertension.mp4\u003cbr\u003e\nHypertension.pdf\u003cbr\u003e\nLipid Management and Risk Assessment in Younger Patients.mp4\u003cbr\u003e\nLipid Management and Risk Assessment in Younger Patients.pdf\u003cbr\u003e\nNew Agents in Lipid Management.mp4\u003cbr\u003e\nNew Agents in Lipid Management.pdf\u003cbr\u003e\nNon-steroidal MRAs in HTN, DM2, and CKD.mp4\u003cbr\u003e\nNon-steroidal MRAs in HTN, DM2, and CKD.pdf\u003cbr\u003e\nPeripartum CV Risk Reduction.mp4\u003cbr\u003e\nPeripartum CV Risk Reduction.pdf\u003cbr\u003e\nPolypill – Quad Study Combo Therapy for BP and Lipids.mp4\u003cbr\u003e\nPolypill – Quad Study Combo Therapy for BP and Lipids.pdf\u003cbr\u003e\nPopulation-Wide Effects and Local Public Health Efforts of Sodium Reduction.mp4\u003cbr\u003e\nPopulation-Wide Effects and Local Public Health Efforts of Sodium Reduction.pdf\u003cbr\u003e\nUpdate in Renal Denervation.mp4\u003cbr\u003e\nUpdate in Renal Denervation.pdf\u003cbr\u003e\nWeight Loss Strategies in Highly Comorbid Patients.mp4\u003cbr\u003e\nWeight Loss Strategies in Highly Comorbid Patients.pdf\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/header\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954634821730,"sku":"MED-AMB07238","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Penn-Medicine-Hypertension-Lipids-and-Approaches-to-CV-Pharmacologic-Risk-Reduction-Whats-New-in-2022.jpg?v=1779381295","url":"https:\/\/meducourse.com\/products\/penn-medicine-hypertension-lipids-and-approaches-to-cv-pharmacologic-risk-reduction-what-s-new-in-2022","provider":"Meducourse","version":"1.0","type":"link"}